Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 251

1.

Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment.

Rolfo C, de Vos-Geelen J, Isambert N, Molife LR, Schellens JHM, De Grève J, Dirix L, Grundtvig-Sørensen P, Jerusalem G, Leunen K, Mau-Sørensen M, Plummer R, Learoyd M, Bannister W, Fielding A, Ravaud A.

Clin Pharmacokinet. 2019 Mar 16. doi: 10.1007/s40262-019-00754-4. [Epub ahead of print]

PMID:
30877569
2.

Metastatic Clear-cell Renal Cell Carcinoma With a Long-term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression.

Kammerer-Jacquet SF, Brunot A, Lefort M, Bayat S, Peyronnet B, Verhoest G, Mathieu R, Lespagnol A, Mosser J, Laguerre B, Ravaud A, Bernhard JC, Dupuis F, Yacoub M, Belaud-Rotureau MA, Bensalah K, Rioux-Leclercq N.

Clin Genitourin Cancer. 2019 Feb 4. pii: S1558-7673(18)30716-X. doi: 10.1016/j.clgc.2019.01.014. [Epub ahead of print]

PMID:
30837208
3.

Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.

Oudard S, Latorzeff I, Caty A, Miglianico L, Sevin E, Hardy-Bessard AC, Delva R, Rolland F, Mouret L, Priou F, Beuzeboc P, Gravis G, Linassier C, Gomez P, Voog E, Muracciole X, Abraham C, Banu E, Ferrero JM, Ravaud A, Krakowski I, Lagrange JL, Deplanque G, Zylberait D, Bozec L, Houede N, Culine S, Elaidi R.

JAMA Oncol. 2019 Jan 31. doi: 10.1001/jamaoncol.2018.6607. [Epub ahead of print]

PMID:
30703190
4.

Dramatic response under combination of immune-oncology in head & neck cancer included in the Condor study: A case report.

Daste A, Digue L, Ravaud A, Domblides C.

Oral Oncol. 2019 Feb;89:150-152. doi: 10.1016/j.oraloncology.2019.01.002. Epub 2019 Jan 11. No abstract available.

PMID:
30639133
5.

Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study.

Gouverneur A, Coutureau J, Jové J, Rouyer M, Grelaud A, Duc S, Gérard S, Smith D, Ravaud A, Droz C, Bernard MA, Lassalle R, Forrier-Réglat A, Noize P; ETNA study group and the EREBUS study group.

Clin Colorectal Cancer. 2018 Nov 29. pii: S1533-0028(18)30247-0. doi: 10.1016/j.clcc.2018.11.005. [Epub ahead of print]

PMID:
30630730
6.

Traitement focal et traitement systémique dans la prise en charge du cancer du rein métastatique : une question de complémentarité.

Salabert L, Sionneau B, Cochin V, Ravaud A, Gross-Goupil M.

Bull Cancer. 2018 Dec;105 Suppl 3:S221-S228. doi: 10.1016/S0007-4551(18)30376-X. French.

PMID:
30595150
7.

Adjuvant therapy after nephrectomy for renal cell carcinoma.

Ravaud A.

Asia Pac J Clin Oncol. 2018 Nov;14 Suppl 5:33-36. doi: 10.1111/ajco.13056. Review.

PMID:
30489037
8.

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.

Staehler M, Motzer RJ, George DJ, Pandha HS, Donskov F, Escudier B, Pantuck AJ, Patel A, DeAnnuntis L, Bhattacharyya H, Ramaswamy K, Zanotti G, Lin X, Lechuga M, Serfass L, Paty J, Ravaud A.

Ann Oncol. 2018 Oct 1;29(10):2098-2104. doi: 10.1093/annonc/mdy329.

9.

Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.

George DJ, Martini JF, Staehler M, Motzer RJ, Magheli A, Donskov F, Escudier B, Li S, Casey M, Valota O, Laguerre B, Pantuck AJ, Pandha HS, Patel A, Lechuga M, Ravaud A.

Clin Cancer Res. 2019 Feb 15;25(4):1165-1173. doi: 10.1158/1078-0432.CCR-18-1724. Epub 2018 Nov 6.

PMID:
30401688
10.

Dramatic response after anti PD1 treatment failure in a squamous cell carcinoma of the maxillary sinus.

Larroquette M, Domblides C, Cousin S, De Gabory L, Dupin C, Ravaud A, Daste A.

Oral Oncol. 2018 Dec;87:207-209. doi: 10.1016/j.oraloncology.2018.10.017. Epub 2018 Oct 18. No abstract available.

PMID:
30343985
11.

Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0235-z.

PMID:
30291359
12.

A cross-sectional assessment of diabetes self-management, education and support needs of Syrian refugee patients living with diabetes in Bekaa Valley Lebanon.

Elliott JA, Das D, Cavailler P, Schneider F, Shah M, Ravaud A, Lightowler M, Boulle P.

Confl Health. 2018 Sep 12;12:40. doi: 10.1186/s13031-018-0174-9. eCollection 2018.

13.

Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial.

Mauge L, Mejean A, Fournier L, Pereira H, Etienne-Grimaldi MC, Levionnois E, Caty A, Abadie-Lacourtoisie S, Culine S, Le Moulec S, Linassier C, Théodore C, Ravaud A, Albiges L, Grine A, Tartour E, Milano G, Gille AS, Verkarre V, Helley D, Oudard S; PREINSUT study group.

Clin Cancer Res. 2018 Nov 15;24(22):5534-5542. doi: 10.1158/1078-0432.CCR-18-1045. Epub 2018 Jul 30.

PMID:
30061359
14.

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T.

Nat Med. 2018 Jun;24(6):749-757. doi: 10.1038/s41591-018-0053-3. Epub 2018 Jun 4. Erratum in: Nat Med. 2018 Dec;24(12):1941.

PMID:
29867230
15.

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

Méjean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G, Rolland F, Linassier C, Lechevallier E, Beisland C, Aitchison M, Oudard S, Patard JJ, Theodore C, Chevreau C, Laguerre B, Hubert J, Gross-Goupil M, Bernhard JC, Albiges L, Timsit MO, Lebret T, Escudier B.

N Engl J Med. 2018 Aug 2;379(5):417-427. doi: 10.1056/NEJMoa1803675. Epub 2018 Jun 3.

16.

Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib.

Rini BI, Escudier B, Martini JF, Magheli A, Svedman C, Lopatin M, Knezevic D, Goddard AD, Febbo PG, Li R, Lin X, Valota O, Staehler M, Motzer RJ, Ravaud A.

Clin Cancer Res. 2018 Sep 15;24(18):4407-4415. doi: 10.1158/1078-0432.CCR-18-0323. Epub 2018 May 17.

PMID:
29773662
17.

Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma.

Dufies M, Nollet M, Ambrosetti D, Traboulsi W, Viotti J, Borchiellini D, Grépin R, Parola J, Giuliano S, Helley-Russick D, Bensalah K, Ravaud A, Bernhard JC, Schiappa R, Bardin N, Dignat-George F, Rioux-Leclercq N, Oudard S, Négrier S, Ferrero JM, Chamorey E, Blot-Chabaud M, Pagès G.

Theranostics. 2018 Mar 28;8(9):2447-2458. doi: 10.7150/thno.23002. eCollection 2018.

18.

Progression beyond nivolumab: Stop or repeat? Dramatic responses with salvage chemotherapy.

Daste A, De-Mones E, Cochin V, Dupin C, Digue L, Ravaud A, Domblides C.

Oral Oncol. 2018 Jun;81:116-118. doi: 10.1016/j.oraloncology.2018.04.013. Epub 2018 Apr 24. No abstract available.

PMID:
29703607
19.

Treatment of spinal metastases in renal cell carcinoma: A critical review.

Teyssonneau D, Gross-Goupil M, Domblides C, Haaser T, Pointillart V, Daste A, Hauger O, Ravaud A.

Crit Rev Oncol Hematol. 2018 May;125:19-29. doi: 10.1016/j.critrevonc.2018.02.017. Epub 2018 Mar 6. Review.

PMID:
29650272
20.

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators.

N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.

21.

Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study.

George DJ, Martini JF, Staehler M, Motzer RJ, Magheli A, Escudier B, Gerletti P, Li S, Casey M, Laguerre B, Pandha HS, Pantuck AJ, Patel A, Lechuga MJ, Ravaud A.

Clin Cancer Res. 2018 Apr 1;24(7):1554-1561. doi: 10.1158/1078-0432.CCR-17-2822. Epub 2018 Jan 26.

PMID:
29374054
22.

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM, Castellano D, Bamias A, Fléchon A, Gravis G, Hussain S, Takano T, Leng N, Kadel EE 3rd, Banchereau R, Hegde PS, Mariathasan S, Cui N, Shen X, Derleth CL, Green MC, Ravaud A.

Lancet. 2018 Feb 24;391(10122):748-757. doi: 10.1016/S0140-6736(17)33297-X. Epub 2017 Dec 18. Erratum in: Lancet. 2018 Oct 20;392(10156):1402.

PMID:
29268948
23.

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.

Patel MR, Ellerton J, Infante JR, Agrawal M, Gordon M, Aljumaily R, Britten CD, Dirix L, Lee KW, Taylor M, Schöffski P, Wang D, Ravaud A, Gelb AB, Xiong J, Rosen G, Gulley JL, Apolo AB.

Lancet Oncol. 2018 Jan;19(1):51-64. doi: 10.1016/S1470-2045(17)30900-2. Epub 2017 Dec 5. Erratum in: Lancet Oncol. 2018 Jul;19(7):e335.

PMID:
29217288
24.

Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.

Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, Dousset L, Pham-Ledard A, Prey S, Beylot-Barry M, Daste A, Gross-Goupil M, Lallier J, Ravaud A, Forcade E, Bannwarth B, Truchetet ME, Richez C, Mehsen N, Schaeverbeke T; FHU ACRONIM.

Ann Rheum Dis. 2018 Mar;77(3):393-398. doi: 10.1136/annrheumdis-2017-212257. Epub 2017 Nov 16.

PMID:
29146737
26.

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K.

Eur Urol. 2018 May;73(5):696-703. doi: 10.1016/j.eururo.2017.09.022. Epub 2017 Oct 23.

PMID:
29074061
27.

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.

Motzer RJ, Ravaud A, Patard JJ, Pandha HS, George DJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Casey M, Serfass L, Pantuck AJ, Staehler M.

Eur Urol. 2018 Jan;73(1):62-68. doi: 10.1016/j.eururo.2017.09.008. Epub 2017 Sep 28.

PMID:
28967554
28.

Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study.

Ravaud A, Gomez-Roca C, Picat MQ, Digue L, Chevreau C, Gimbert A, Chauzit E, Sitta R, Cornelis F, Asselineau J, Aziza R, Daste A, Quemener C, Baud J, Bikfalvi A, Pedenon-Périchout D, Doussau A, Molimard M, Delord JP.

Eur J Cancer. 2017 Nov;85:39-48. doi: 10.1016/j.ejca.2017.07.031. Epub 2017 Sep 5.

PMID:
28886476
29.

[Principles, modalities and indications of the administration of Radium in cancers, focus on metastatic prostate cancer: State of arts].

Bertolaso P, Leroy L, Gross-Goupil M, Aupee O, Ravaud A, Roubaud G, Cazeau AL, Le Moulec S.

Bull Cancer. 2017 Sep;104(9):762-770. doi: 10.1016/j.bulcan.2017.06.011. Epub 2017 Aug 7. Review. French.

PMID:
28797482
30.

Immune checkpoint inhibitors and elderly people: A review.

Daste A, Domblides C, Gross-Goupil M, Chakiba C, Quivy A, Cochin V, de Mones E, Larmonier N, Soubeyran P, Ravaud A.

Eur J Cancer. 2017 Sep;82:155-166. doi: 10.1016/j.ejca.2017.05.044. Epub 2017 Jul 6. Review.

PMID:
28689093
31.

Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatment.

Kammerer-Jacquet SF, Brunot A, Bensalah K, Campillo-Gimenez B, Lefort M, Bayat S, Ravaud A, Dupuis F, Yacoub M, Verhoest G, Peyronnet B, Mathieu R, Lespagnol A, Mosser J, Edeline J, Laguerre B, Bernhard JC, Rioux-Leclercq N.

Urol Oncol. 2017 Oct;35(10):603.e7-603.e14. doi: 10.1016/j.urolonc.2017.05.015. Epub 2017 Jun 12.

32.

Pulmonary arterial hypertension due to an intratumoral shunt: an unexpected side effect of sunitinib.

Daste A, Laine M, Gross-Goupil M, Bernhard JC, François L, Ravaud A.

Future Oncol. 2017 Jun;13(14):1219-1221. doi: 10.2217/fon-2017-0012. Epub 2017 Jun 13. No abstract available.

PMID:
28606002
33.

Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.

Noize P, Grelaud A, Bay JO, Chevreau C, Gross-Goupil M, Culine S, Ferrière JM, Moulin F, Robinson P, Balestra A, Lamarque S, Bernard MA, Lassalle R, Rouyer M, Droz-Perroteau C, Moore N, Fourrier-Réglat A, Ravaud A.

Pharmacoepidemiol Drug Saf. 2017 Dec;26(12):1561-1569. doi: 10.1002/pds.4228. Epub 2017 Jun 1.

PMID:
28573786
34.

Drug Interaction With Sunitinib and the Evidence of Therapeutic Drug Monitoring: A Case Report and Review of the Literature.

Bertolaso P, Gross-Goupil M, Molimard M, Cochin V, Ravaud A, Daste A.

Clin Genitourin Cancer. 2017 Oct;15(5):e885-e887. doi: 10.1016/j.clgc.2017.05.004. Epub 2017 May 10. Review. No abstract available.

PMID:
28552572
35.

Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy.

Kammerer-Jacquet SF, Medane S, Bensalah K, Bernhard JC, Yacoub M, Dupuis F, Ravaud A, Verhoest G, Mathieu R, Peyronnet B, Brunot A, Laguerre B, Lespagnol A, Mosser J, Dugay F, Belaud-Rotureau MA, Rioux-Leclercq N.

Target Oncol. 2017 Aug;12(4):487-494. doi: 10.1007/s11523-017-0498-1.

PMID:
28550387
36.

Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected response.

Teyssonneau D, Daste A, Dousset V, Hoepffner JL, Ravaud A, Gross-Goupil M.

BMC Cancer. 2017 May 11;17(1):323. doi: 10.1186/s12885-017-3309-2.

37.

[Cabozantinib: Mechanism of action, efficacy and indications].

Cochin V, Gross-Goupil M, Ravaud A, Godbert Y, Le Moulec S.

Bull Cancer. 2017 May;104(5):393-401. doi: 10.1016/j.bulcan.2017.03.013. Epub 2017 May 3. French.

PMID:
28477875
38.

Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.

Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, Hammers HJ, Donskov F, Gurney H, Sosman JA, Zalewski PG, Harmenberg U, McDermott DF, Choueiri TK, Richardet M, Tomita Y, Ravaud A, Doan J, Zhao H, Hardy H, George S.

Eur Urol. 2017 Sep;72(3):368-376. doi: 10.1016/j.eururo.2017.03.037. Epub 2017 Apr 12.

PMID:
28410865
39.

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.

Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, Mega AE, Britten CD, Ravaud A, Mita AC, Safran H, Stinchcombe TE, Srdanov M, Gelb AB, Schlichting M, Chin K, Gulley JL.

J Clin Oncol. 2017 Jul 1;35(19):2117-2124. doi: 10.1200/JCO.2016.71.6795. Epub 2017 Apr 4.

40.

A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.

Ravaud A, de la Fouchardière C, Caron P, Doussau A, Do Cao C, Asselineau J, Rodien P, Pouessel D, Nicolli-Sire P, Klein M, Bournaud-Salinas C, Wemeau JL, Gimbert A, Picat MQ, Pedenon D, Digue L, Daste A, Catargi B, Delord JP.

Eur J Cancer. 2017 May;76:110-117. doi: 10.1016/j.ejca.2017.01.029. Epub 2017 Mar 20.

PMID:
28301826
41.

Adjuvant Sunitinib in Renal-Cell Carcinoma.

Ravaud A.

N Engl J Med. 2017 Mar 2;376(9):893. doi: 10.1056/NEJMc1616636. No abstract available.

PMID:
28249133
42.

Relationship between Pulmonary Adverse Events and Everolimus Exposure in Japanese and Non-Japanese Patients: A Meta-Analysis of Oncology Trials.

Noguchi S, Shinohara N, Ito T, Ohtsu A, Ravaud A, Jerusalem G, Ohno N, Gallo J, Bouillaud E, Fan J, Nonomura N.

Oncology. 2017;92(5):243-254. doi: 10.1159/000457904. Epub 2017 Feb 21.

PMID:
28219073
43.

A prospective observational study on the evaluation of everolimus-related adverse events in metastatic renal cell carcinoma after first-line anti-vascular endothelial growth factor therapy: the AFINITE study in France.

Joly F, Eymard JC, Albiges L, Nguyen T, Guillot A, Rolland F, Spaeth D, Laguerre B, Lebret T, Kelkouli N, Slimane K, Ravaud A.

Support Care Cancer. 2017 Jul;25(7):2055-2062. doi: 10.1007/s00520-017-3594-y. Epub 2017 Feb 10.

PMID:
28188447
44.

Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas.

Dufies M, Giuliano S, Ambrosetti D, Claren A, Ndiaye PD, Mastri M, Moghrabi W, Cooley LS, Ettaiche M, Chamorey E, Parola J, Vial V, Lupu-Plesu M, Bernhard JC, Ravaud A, Borchiellini D, Ferrero JM, Bikfalvi A, Ebos JM, Khabar KS, Grépin R, Pagès G.

Cancer Res. 2017 Mar 1;77(5):1212-1226. doi: 10.1158/0008-5472.CAN-16-3088. Epub 2017 Jan 13.

45.

Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study.

Gore ME, Jones RJ, Ravaud A, Kuczyk M, Demkow T, Bearz A, Shapiro J, Strauss UP, Porta C.

BJU Int. 2017 Jun;119(6):846-853. doi: 10.1111/bju.13740. Epub 2017 Jan 9.

46.

Is Multiparametric MRI Useful for Differentiating Oncocytomas From Chromophobe Renal Cell Carcinomas?

Galmiche C, Bernhard JC, Yacoub M, Ravaud A, Grenier N, Cornelis F.

AJR Am J Roentgenol. 2017 Feb;208(2):343-350. doi: 10.2214/AJR.16.16832. Epub 2016 Dec 13.

PMID:
27959744
47.

Targeted therapy and elderly people: A review.

Daste A, Chakiba C, Domblides C, Gross-Goupil M, Quivy A, Ravaud A, Soubeyran P.

Eur J Cancer. 2016 Dec;69:199-215. doi: 10.1016/j.ejca.2016.10.005. Epub 2016 Nov 15. Review.

PMID:
27855351
48.

Immunotherapy in head and neck cancer: Need for a new strategy? Rapid progression with nivolumab then unexpected response with next treatment.

Daste A, de Mones E, Digue L, François L, Domblides C, Dupin C, Bigourdan A, Ravaud A.

Oral Oncol. 2017 Jan;64:e1-e3. doi: 10.1016/j.oraloncology.2016.10.020. Epub 2016 Nov 3. No abstract available.

PMID:
27818058
49.

Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered.

Stewart GD, Aitchison M, Bex A, Larkin J, Lawless C, Méjean A, Nathan P, Oades G, Patard JJ, Paul J, Ravaud A, Escudier B; Renal Cross Channel Group.

Eur Urol. 2017 Jun;71(6):845-847. doi: 10.1016/j.eururo.2016.10.029. Epub 2016 Nov 1.

PMID:
27815086
50.

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Martini JF, Ramaswamy K, Casey M, Staehler M, Patard JJ; S-TRAC Investigators.

N Engl J Med. 2016 Dec 8;375(23):2246-2254. Epub 2016 Oct 9.

Supplemental Content

Loading ...
Support Center